Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine
This morning’s news is a mixed bag for Pfizer $PFE, which reported updates on two different pipeline drugs first thing Monday. One program saw a positive development, while the other was slapped with a setback.
Let’s start with the bad news. The pharma giant said regulators have rejected its trastuzumab biosimilar, which was intended as a cheaper version of Roche’s cancer drug Herceptin. Pfizer placated investors by pointing out that the FDA asked for more technical information to support the application, not for safety or clinical data information.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.